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Objectives. This study sought to describe in detail the pharma- 
cokinetics and pharmacodynamics of chimeric monoclonal 7E3 
Fab (c7E3 Fab) and to compare platelet responses to adenosine 
diphosphate (ADP) and the ll-amino acid thrombin receptor- 
activating peptide (TRAP [SFLLRNPNDKY.NHz] ) in patients 
undergoing elective coronary angioplasty. 
Background. Inhibition of platelet aggregation with monoclonal 
antibody c7E3 Fab directed against glycoprotein (GP) Ilb/lIIa has 
been shown to reduce ischemic complications after angioplasty 
and is being considered for treatment of other acute ischemic 
syndromes. 
Methods. Patients undergoing elective coronary angioplasty 
received aspirin (325 mg orally), heparin (12,000 U intravenously) 
and a bolus of c7E3 Fab (0.25 mg/kg body weight). Surface 
GPllb/IIIa receptor blockade and aggregation in response to 20 
pmol/iiter ADP, 5 pg/ml collagen and 7.5 and 15/xmol/liter TRAP 
were assessed. 
Results. Surface GPIIb/IIIa receptor blockade by c7E3 Fab was 
80% 2 h after injection and decreased to 50% at 24 h. Platelet 
aggregation in response to 20 pmol/liter ADP was inhibited by 
73% at 2 h, and this inhibition decreased to 27% at 24 h. Platelet 
aggregation in response to 7.5 pmol/liter TRAP was inhibited by 
53% at 2 h and 30% at 24 h. In contrast, aggregation in response 
to 15 pmol/liter TRAP was inhibited only 37% at 2 h and 10% at 
24 h (p < 0.001 and p = 0.006, respectively vs. 20 pmol/liter ADP). 
Addition of exogenous c7E3 Fab to platelet.rich plasma led to 
more complete inhibition of 7.5 pmol/liter TRAP-induced aggre- 
gation. 
Conclusions. After c7E3 Fab treatment, inhibition of platelet 
aggregation depends on the agonist and can be overcome by 
increased thrombin activity but is restored if additional c7E3 Fab 
is added to block additional GPIlb/llla receptors. This phenom- 
enon may be related to an internal pool of GPIIb/llIa receptors 
joining the surface membrane and has implications concerning 
the duration of therapy with c7E3 Fab for patients with unstable 
angina or acute myocardial infarction. 
(J Am Coil Cardiol 1995;26:1665-71) 
Inhibition of platelet function with aspirin is beneficial in a 
variety of clinical syndromes, including acute myocardial in- 
farction (1), stroke (2) and unstable angina (3,4). Considerably 
more potent antagonists of platelet aggregation have been 
developed recently that interfere with the binding of fibrino- 
gen, yon Willebrand factor and perhaps other adhesive glyco- 
proteins to the surface glycoprotein receptor IIb/IIIa (GPIIb/ 
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IIIa, integrin alphaiib-beta3). One of these agents, the chimeric 
monoclonal ntibody Fab fragment 7E3 (c7E3 Fab), has been 
shown to reduce ischemic omplications after percutaneous 
transluminal coronary angioplasty (5). Although the antiaggre- 
gatory properties of this compound have been studied in a 
small dose-ranging study (6), the details of its pharmacokinetic 
and pharmacodynamic properties have not been reported. 
A number of different physiologically occurring agonists 
cause platelet aggregation i  vivo and can also be studied in 
vitro. These compounds include collagen exposed on the 
surface of a ruptured plaque; adenosine diphosphate (ADP), 
which may be released from platelet-dense granules or during 
the lysis of red blood cells subjected to high shear forces at the 
site of severe arterial narrowing; and thrombin, generated as 
thrombi are formed and lysed. Because aspirin incompletely 
inhibits aggregation of platelets exposed to the former two 
agents, which have traditionally been used to study platelet 
aggregation in patients treated with GPIIb/IIIa inhibitors, until 
(c~1995 by the Amclicm/ (~llcgc t~lq aldit~l~,~,~ 0735-1097/95/$9.50 
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now technical limitations related to clot formation have pre- 
cluded reliably studying the effects of thrombin on platelets 
from these patients. 
Recently, identification and cloning of the platelet hrom- 
bin receptor have allowed the identification of a thrombin 
cleavage site near the amino terminus of the receptor. Expo- 
sure of platelets to peptides with the sequence of the new 
amino terminus after thrombin cleavage, known as thrombin 
receptor-activating peptides (TRAP), mimics thrombin stimu- 
lation and causes platelet activation and aggregation (7-10). 
Because thrombin has been implicated as perhaps the most 
important platelet agonist initiating thrombosis in vivo, we 
wanted to assess the impact of c7E3 Fab treatment on aggre- 
gation induced by this powerful and important agonist. Ac- 
cordingly, the present study was designed to determine the 
clearance rates of c7E3 Fab from plasma nd to compare the 
time course of GPIIb/IIIa receptor blockade as judged by 
the responses to ADP, collagen and a TRAP in patients who 
had been treated with c7E3 Fab before coronary angioplasty. 
Methods 
Patients. Patients were eligible for the study if they were 
between 21 and 75 years old and scheduled to undergo elective 
coronary angioplasty at The Methodist Hospital or Ben Taub 
General Hospital, Houston, Texas. Exclusion criteria included 
history of hemorrhagic diathesis, heparin or aspirin intoler- 
ance, left main coronary artery narrowing >50% unless pro- 
tected by coronary bypass graft, major operation within 
6 weeks, oral anticoagulant or antiplatelet (other than aspirin) 
administration within 14 days, administration f dextran or a 
thrombolytic agent within 48 h, history of retinal hemorrhage 
or stroke, history of vasculitis, prior treatment with murine- 
derived proteins or inability to give informed consent. The 
study protocol was approved by the human studies review 
boards at both institutions and at Baylor College of Medicine; 
all participating patients gave written informed consent. 
Angioplasty procedure. Angioplasty procedures were per- 
formed in the standard manner from the femoral approach 
through 8F or 9F sheaths. All patients received premedication 
with 325 mg of aspirin 2 to 6 h before the administration f 
c7E3 Fab. Immediately after sheath placement, a blood sample 
was drawn through the sheath for platelet aggregation studies, 
and a 12,000-U bolus of heparin was administered intrave- 
nously. Additional heparin was given to maintain the activated 
clotting time (Hemotec) in excess of 300 s. After 10 min had 
elapsed, another blood sample was obtained for aggregation 
studies, after which the bolus of c7E3 Fab was given intrave- 
nously. After 5 rain more, the guide wire was placed across the 
designated coronary artery narrowing, and the balloon was 
advanced and the lesion dilated using standard techniques. 
After the procedure, patients were taken to the coronary care 
unit or an intermediate care unit, where the sheath was left in 
place for a minimum of 6 h, and a heparin infusion was 
initiated at 800 U/h and adjusted to maintain the activated 
partial thromboplastin time between 65 and 90 s. The sheath 
was removed, and standard manual compression was applied 
4 h after discontinuation f the heparin. In the event of a 
coronary dissection or an unsatisfactory result, heparin could 
be restarted and continued at the discretion of the physician 
performing the angioplasty procedure. 
c7E3 Fab. Chimeric 7E3 Fab (Centocor, Inc.) was admin- 
istered to patients as a single bolus in a dose of 0.25 mg/kg 
body weight. The study drug was produced in one of three lots, 
in either St. Louis, Missouri or Leiden, The Netherlands. 
Patients were randomly assigned by blinded vial numbers to 
receive c7E3 Fab from one of the three lots. The drug was 
administered asan intravenous bolus over 1 min with heart 
rate and blood pressure monitoring. 
Blood samples. Blood samples were drawn at the following 
times for platelet aggregation: baseline (immediately before 
administration of heparin), 10 min after administration of
heparin and 2, 6 and 24 h after administration f the c7E3 Fab. 
Blood samples for determination f plasma c7E3 Fab levels 
were drawn through the venous sheaths immediately before 
and 10 rain after heparin administration, immediately before 
the c7E3 Fab bolus and 2, 5, 10, 20, 30 and 60 min as well as 
2, 4, 6, 12, 24 and 48 h after the bolus had been given. 
Platelet aggregation. All platelet aggregation studies were 
performed by the same technician in the same laboratory. 
Blood was collected in tubes containing 3.8% sodium citrate. 
Platelet-rich plasma was prepared by centrifugation f blood at 
room temperature at 150 × g for 10 min. Platelet-poor plasma 
was prepared by recentrifuging the supernatant from the 
platelet-rich plasma preparation at 1,700 × g for 15 min. The 
platelet count of platelet-rich plasma was subsequently deter- 
mined with a particle counter (Coulter) and adjusted to 
250,000 ___ 50,000 platelets/ml by dilution with platelet-poor 
plasma. Platelet aggregation values were considered valid only 
if the platelet count in the platelet-rich plasma was >125,000/ 
mm 3. Platelet aggregation was determined at37°C in a PAP-4 
(Biodata) four-channel optical aggregometer in response to 
saline solution and the following agonists (reported as final 
concentrations): 5 and 20/stool/liter ADP, 5/zg/ml of collagen 
and the ll-amino acid (SFLLRNPNDKY-NH2) thrombin 
receptor-activating peptide (TRAP), prepared as previously 
described (9,10), in final concentrations of 7.5 and 15/xmol/ 
liter. The former concentration was used to study aggregation 
in 14 patients and the latter in 16 patients. In eight patients, the 
response to 7.5/xmol/liter TRAP was studied in blood samples 
taken 5 min after the administration f c7E3 Fab. Results of 
the assays were recorded as percent light transmission 4 min 
after addition of the agonists to platelet-rich plasma nd were 
reported as percent inhibition compared with the baseline 
(postheparin) value. In cases in which the postheparin value 
was not available, the post-c7E3 Fab values were not analyzed. 
In 12 patients, the aggregation response to 12.5 /~mol/liter 
TRAP was measured in the 2-h sample after the addition of 
exogenous c7E3 Fab in final concentrations of 0.125, 0.5 and 
1.0 tzg/ml. 
Platelet-binding assay. The extent of GPIIb/IIIa receptor 
blockade by c7E3 Fab was determined in platelet-rich plasma 
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for all patients. Platelets were incubated ex vivo with a near- 
saturating final concentration (0.018 mg/ml) of iodine- 
125-labeled murine 7E3 immunoglobulin (Ig) (11) dissolved in 
0.05 mol/liter Tris-HCl, 0.15 tool/liter NaCI, pH 7.4. Forty 
microliters of the tracer was mixed gently with 0.36 ml of 
platelet-rich plasma and incubated for 30 min at room tem- 
perature, conditions under which binding reaches equilibrium. 
Aliquots of 100 ~1 of the mixture were then layered onto 0.2 ml 
of 30% sucrose solution. This procedure was performed in 
triplicate. Each specimen was then centrifuged at 10,000 x g at 
room temperature. The pellet was then removed, and both the 
pellet and supernatant were counted in a gamma spectrometer 
for 1 min. The triplicate counts were averaged, and the bound 
fraction (B) was calculated as equal to (pellet cpm)/(pellet + 
supernatant cpm). Previous studies (11) have demonstrated 
that under these conditions, -99% of the antibody binding is 
specific. The number of molecules of 7E3 antibody bound/ 
platelet was then calculated as follows: 
B × 1.8/xg 7E3 IgG × 3.76 x 10 ~2 Molecules//xg 
Piatelet count//zl x 90 pJ 
Plasma 7E3 levels and pharmaeokinetic alculations. 
Citrate-anticoagulated blood was collected, and platelet-poor 
plasma was immediately prepared. Free plasma concentrations 
of c7E3 Fab were determined using an enzyme-linked immu- 
nosorbent assay (ELISA) employing an atfinity-purified prep- 
aration of rabbit antibodies prepared against he routine 7E3 
variable regions. A biotinylated conjugate of the rabbit anti- 
body preparation coupled with horseradish peroxidase- 
streptavidin was used for detection. Pharmacokinetic analysis 
of the concentration versus time was performed using a 
nonlinear least-squares fit to a two-compartment model 
(Minsq, Micromath, Inc.). A similar model has previously been 
used to characterize the pharmacokinetics of antibodies and 
their fragments (12). 
Statistical methods. Differences between inhibition of 
platelet aggregation i response to the two concentrations of 
ADP and collagen at 2, 6 and 24 h were assessed using the 
Friedman chi-square test. Differences between ADP 20 gmol/ 
liter and TRAP 15 /~mol/liter and 20/~mol/]iter and TRAP 
7.5 /~mol/liter at 2, 6 and 24 h were evaluated using the 
Wilcoxon signed-rank test. To test the difference between 
TRAP 15 ~mol/liter and TRAP 7.5 /~mol/liter, the Wilcoxon 
two-sample test was used. Correlations between the numbers 
of available binding sites and platelet aggregation and between 
peak plasma concentration and platelet aggregation were 
assessed using Spearman rank correlations. Differences be- 
tween 2-h, 6-h and 24-h time points of percent blockade of 
GPII/IIIa binding sites were analyzed using repeated-measures 
analysis. 
Results 
Patients. A total of 32 patients representing a typical 
population undergoing coronary, angioplasty were treated. 
Their baseline characteristics are shown in Table 1. There were 
Table 1. Baseline Demographic Characteristics 
Age (yr) 58 + 8 
Male/female 20/12 
Weight (kg) 85 + 17 
MI within 30 days 9 
Heparin bolus (U) 12,800 -- 1,820 
Vessel dilated 
LAD 1 l 
LCx 11 
RCA 10 
Hemoglobin (gjdl) 13.3 _+ 2.5 
Platelet ( 1,000/mm ~) 229 _+ 43 
WBC count ( 1,001)/mm 3) 7.8 + 2.1 
Data presented are mean value + SD or number of patients. LAD = left 
anterior descending coronary artery; LCx = left circumflex coronary artery; 
MI - myocardial infarction; RCA = right coronary artery; WBC = white blood 
cell. 
no deaths or myocardial infarctions. One patient required 
placement of an intracoronary stent for a coronary dissection 
with threatened closure. One patient received a blood trans- 
fusion in preparation for coronary artery bypass urgery on the 
fourth day after treatment. 
Pharmaeokinetics. Pharmacokinetics of c7E3 Fab are dis- 
played in Figure 1. The curve is the model fit to points represent- 
ing mean plasma concentrations. Because of what appeared to 
be a biphasic peak of c7E3 Fab concentrations, the first value 
used in the model was the sample taken at 10 min. In a 
two-compartment model, the calculated distribution phase 
(alpha half-life) of the c7E3 Fab bolus was 26 rain, and the 
catabolic phase (beta half-life) was 7 h. Because c7E3 Fab 
begins to bind to platelets within seconds after administration, 
the calculated alpha half-life is probably longer than the actual 
half-life. At 2 h, <4% of the total injected dose is present as 
free plasma antibody. 
Receptor blockade and platelet aggregation studies. The 
blockade of GPIIb/IIIa receptor sites is shown in Figure 2. As 
in previous tudies (13,14), the number of free receptors was 
reduced by -80% in the first (2 h) sample and returned to 
-50% of the baseline value by 24 h. Fourteen patients had 
Figure I. Modeled (two-compartment) pharmacokinetic clearance of
c7E3 Fab from plasma fter a bolus dose. The calculated alpha half-life 
is 26 rain, and the beta, or redistribution, half-life is 7 h. 
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Figure 2. Receptor binding site blockade shown as percent of baseline 
value of available r ceptors after 2, 6 and 24 h. Data shown are mean 
value (plus signs), median (25th, 75 percentiles) (horizontal lines), 
values 1.5 times the interquartile range (solid vertical lines), values 
between 1.5 and 3 times the interquartile range (ovals) and values lying 
>3 times beyond the bounds of the interquartile range (asterisk). 
surface receptor blockade >80% at 2 h, but none had this 
degree of blockade at 24 h. Figure 3 shows the responses of 
platelet aggregation to the agonists collagen and ADP. There 
was nearly complete inhibition of aggregation i  response to 
collagen and the lower concentration f ADP, and in response 
to the 20-~tmol/liter concentration f ADP, aggregation was 
inhibited by 76% (mean value) at the 2-h sample and -27% 
(mean value) at 24 h (Fig. 3). The differences among the 
responses to the three agonists are significant at each time 
point studied (p < 0.001 for each point). 
Responses to the two concentrations of TRAP are shown in 
Figure 4. The studies at the two concentrations of the TRAP 
agonist were performed insequential groups of patients. There 
were no differences between these two groups in baseline 
characteristics, peak plasma concentrations of c7E3 Fab or 
response to ADP or collagen. Although there were not signif- 
icant differences in inhibition of aggregation i response to the 
two concentrations, there were trends toward less inhibition in 
response to the higher concentration at all three of the time 
points studied. The responses to ADP are shown in compari- 
son to TRAP for each group of patients (Fig. 5). Compared 
with 20 ~mol/liter ADP, 7.5/zmol/liter TRAP-induced aggre- 
gation was less inhibited 2and 6 h after the bolus injection of 
c7E3 Fab, and at 24 h slightly but not significantly more 
inhibited (inhibition: ADP 73%, 49% and 20%; TRAP 53%, 
38% and 61% at 2, 6 and 24 h, respectively [p = 0.014, p = 
0.301, and p = 0.359, respectively]) (Fig. 5, top). Aggregation 
in response to the higher concentration of TRAP (Fig. 5, 
bottom) was significantly less inhibited at 2 and 6 h after the 
bolus injection compared with the response to 20/zmol/liter 
ADP. At 24 h, this difference had narrowed considerably 
(inhibition: ADP 79%, 64% and 32%; TRAP 37%, 32% and 
8% at 2, 6 and 24 h, respectively [p < 0.001, p < 0.001, and 
p -- 0.006, respectively]). 
c7E3 Fab concentration and platelet aggregation. There 
was no correlation between circulating levels of plasma c7E3 
Fab at 10 min (peak) and inhibition of aggregation i response 
to ADP, and a weak correlation with the response to 15/~mol/ 
liter TRAP (Table 2). However, inhibition did correlate with 
the degree of blockade of platelet GPIIb/IIIa receptors. Be- 
cause the circulating concentrations of c7E3 Fab were high in 
the early minutes after the c7E3 Fab injection, aggregation i
response to 7.5 txmol/liter TRAP was measured in eight 
patients 5 rain after the injection of c7E3 Fab. The mean 
(_+SD) plasma concentration f c7E3 Fab at this point was 
2.4 _+ 0.4/zg/ml. In these patients, the degree of inhibition of 
the aggregation response to 7.5 ~tmol/liter was maximal at 
5 min and progressively decreased over time (Fig. 6). When 
exogenous c7E3 Fab was added to the platelet-rich plasma 
obtained 2 h after c7E3 Fab injection to achieve higher 
concentrations of c7E3 Fab, aggregation i response to TRAP 
was virtually eliminated (Fig. 7). 
Discussion 
We showed that c7E3 Fab is characterized by a brief plasma 
half-life but a longer biologic half-life. Despite virtually unde- 
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Figure 3. Platelet aggregation in response to5 and 
20 /~mol/liter adenosine diphosphate (ADP) and 
collagen (5/zg/liter), shown as a percent of baseline 
value (mean values, respectively, 24%, 12% and 15% 
at 2 h; 42%, 27% and 17% at 6 h; 73%, 61% and 33% 
at 24 h). Format and symbols as in Figure 2. 
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tectable plasma levels 6 h after injection of a bolus dose, nearly 
50% of the surface GPIIb/IIIa receptors on each platelet were 
still blocked, and aggregation i response to the agonists ADP 
and collagen was still significantly inhibited. Conversely, aggre- 
gation in response to the l 1-amino acid thrombin receptor- 
activating peptide was more robust. There was a weak corre- 
lation between plasma levels of circulating c7E3 Fab and the 
degree of inhibition of TRAP-induced aggregation, and there 
was a trend toward association between plasma levels and 
inhibition of platelet aggregation i duced by ADP. The degree 
of inhibition of aggregation i duced by ADP correlated signif- 
icantly with the degree of GPIIb/IIIa receptor blockade, and 
there was a trend toward correlation between receptor block- 
ade and inhibition of TRAP-induced aggregation (Table 2). 
Mechanistic implications. The short plasma half-life of 
c7E3 Fab is most likely related to its rapid binding to exposed 
GPIIb/IIIa receptors on the surface of circulating platelets. 
The plasma alpha half-life is likely to be even shorter than the 
26 min calculated in this study because the first value used for 
calculation was the level obtained 10 rain after the bolus 
injection. In a previous tudy (14), patients with thrombocyto- 
sis were found to have a diminished response to c7E3 Fab, 
presumably because of the increased number of GPIIb/IIIa 
receptors that required blockade. 
The events following the platelet equilibration phase, how- 
ever, deserve comment. The prolonged inhibition of aggrega- 
tion induced by the weak agonist ADP and a low concentration 
of collagen probably reflects continued presence of c7E3 Fab 
on the platelet surface receptors. On the other hand, stimula- 
tion of these platelets with TRAP was able to produce 
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Figure 5. Platelet aggregation i response to adenosine diphosphate 
(ADP) 20 /zmol/liter and thrombin receptor-activating peptide 
(TRAP), either 7.5 p, mol/liter (top) or 15 p, mol/liter (bottom), shown 
as percent of baseline value at 2, 6 and 24 h after injection of c7E3 Fab 
bolus. Mean values, respectively: (top) 27% vs. 47% at 2 h; 51% vs. 
62% at 6 h; 80% vs. 39% at 24 h; (bottom) 21% vs. 63% at 2 h; 36% 
vs. 68% at 6 h; 68% vs. 92% at 24 h. Because the two concentrations 
of TRAP were studied in sequential groups of patients, responses to 
ADP for each TRAP group are displayed separately. Format and 
symbols as in Figure 2. 
aggregation. Previous investigators have shown that exposure 
of platelets to thrombin causes an increase in the number of 
GPIIb/IIIa receptors available on the platelet surface (15-17) 
through externalization of receptors in the alpha granule 
membranes and perhaps other sites during the release reac- 
tion. If this process were to occur when all available stores of 
c7E3 Fab were already bound to receptors, then the free 
receptors induced by TRAP would be able to support some 
aggregation, and the observed inhibition would be less than 
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Table 2. Correlations Between I hibition of Aggregation, Plasma 
7E3 Concentration a d Receptor Blockade 
Agonist 
Correlation of Spearman 
Inhibition at Rank p 
2 h With Coefficient (rho) Value 
TRAP 7.5/zmol/liter Peak plasma cone -0.282 0.401 
TRAP 15/xmol/liter Peak plasma cone -0.588 0.035 
ADP 20 ,o, mol/liter % receptor blockade -0.454 0.034 
TRAP 7.5/zrnol/liter % receptor blockade 0.573 0.066 
TRAP 15/.tmol/liter % receptor blockade 0.564 0.071 
ADP = adenosine diphosphate; cone = concentration: TRAP = thrombin 
receptor-activating peptidc. 
with other agents that do not induce the release reaction. 
Consistent with this hypothesis was our observation that the 
samples drawn at 5 min, the earliest ime point, showed more 
inhibition of aggregation because circulating levels of c7E3 
Fab were still significant and thus were available to bind to the 
newly exposed GPIIb/IIIa receptors. To test the hypothesis 
more directly, we added exogenous c7E3 Fab to platelet-rich 
plasma samples drawn 2 h after c7E3 Fab injection and tested 
the response to 7.5/zmol/liter TRAP. The untreated platelet- 
rich plasma had a mean aggregation inhibition of -50% 
compared to pretreatment. Addition of 1 ~zg/ml of c7E3 Fab 
increased the inhibition to -90%. Thus, these data indicate 
that TRAP-induced platelet aggregation can be inhibited 
effectively by c7E3 Fab but that an adequate free plasma 
concentration is required. 
Clinical implications. These findings have several clinical 
implications. 
1. In the Evaluation of c7E3 Fab for the Prevention of 
Ischemic Complications (EPIC) study (5) of 2,099 patients 
undergoing coronary angioplasty, a bolus followed by a 12-h 
Figure 6. Platelet aggregation i  response to thrombin receptor- 
activating peptide (12.5 gmol/liter) in the eight patients in whom 
samples were available 5 min after c7E3 Fab injection. The solid line 
connects he mean values. At 5 rain, when concentrations f c7E3 Fab 
are highest, he inhibition of aggregation is the greatest, suggesting 
that saturation f surface GPllb/llla receptors is nearer to a maximum 
at this point. 
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bolus) after the addition of exogenous c7E3 Fab. Horizontal bars = 
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infusion of c7E3 Fab reduced recurrent ischemic events (pre- 
dominantly emergent revascularization a d acute myocardial 
infarction), but a bolus alone was considerably ess effective. 
One possible xplanation for the relative inefficacy of the bolus 
dose alone is that intense stimulation of platelets as may occur 
when thrombin-rich mural thrombi form at the site of a 
damaged vascular wall after angioplasty (18). This intense 
stimulation can still induce aggregation despite initial blockade 
of the surface GPIIb/IIIa receptors if the plasma level of eTE3 
Fab is insufficient to inhibit newly exposed GPIIb/IIIa recep- 
tors from the interior of the platelet. Alternatively, the infusion 
may have been needed to produce inhibition for sufficient 
duration to allow a "passivation" process that renders the 
surface less thrombogenic (19). 
2. In patients in whom intravascular thrombin generation is 
particularly intense, such as those with unstable angina (20) or 
those undergoing thrombolysis for acute myocardial infarction 
(21), prolonged rather than brief infusions of GPIIb/IIIa 
inhibitors may be required to prevent myocardial infarction or 
reinfarction from occurring, and combination with a potent 
thrombin inhibitor is likely to be effective. 
3. With regard to the safety of GPIIb/IIIa inhibition, there 
was an excess of bleeding in patients in the EPIC study who 
received heparin, aspirin and c7E3 Fab, but life-threatening 
bleeding complications were exceedingly rare despite the fact 
that a 0.25-mg/kg bolus of c7E3 Fab produces nearly uniform 
marked prolongation of bleeding time (13,14,22). It may be 
that c7E3 Fab leaves platelet adhesion relatively intact (23), 
allowing the deposition of a platelet monolayer, or perhaps 
because intense stimuli at sites of vascular injury are sufficient 
to induce surface xposure of internal GPIIb/IIIa stores, which 
may not be inhibited when the plasma level of c7E3 Fab 
declines. 
Study limitations. The current study has several imita- 
tions: 1) Because the amount of blood required to be drawn in 
this study was considerable, we did not obtain enough addi- 
tional plasma to perform dose-response studies with the 
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TRAP agonist o determine the response to ADP and collag- 
en-induced aggregation at the 5-min point or to assess the 
response of ADP and collagen-induced aggregation to exog- 
enously added c7E3 Fab. 2) Because the study was designed 
and executed before the completion of the EPIC study, we 
studied the effects of a bolus alone rather than a bolus 
combined with an infusion of c7E3 Fab. It is possible that the 
sustained high plasma levels of c7E3 Fab that occur when a 
bolus of c7E3 Fab is followed by a continuous infusion would 
successfully block the additional receptors that are expressed 
after exposure to thrombin. Moreover, because there appears 
to be recirculation of the GPIIb/IIIa receptor pool between the 
internal and external compartments, and antibodies to the 
GPIIb/IIIa receptor may become internalized, a longer infu- 
sion of c7E3 Fab may lead to the occupancy of receptors in 
both pools, leading to inhibition of the response to TRAP, 
even when it induces the release reaction. 3) The absence of a 
control group of patients did not allow us to determine 
whether some of the changes observed resulted from the 
angioplasty procedure rather than c7E3 Fab administration, 
but other studies (6) of platelet aggregation during angioplasty 
have not identified a significant effect of the procedure itself. 
Because patients undergoing coronary angioplasty are custom- 
arily treated with aspirin, it is difficult to predict what the 
results would have been in platelets that had not been exposed 
to aspirin. Although it is possible that had baseline aggregation 
in response to ADP and collagen been more pronounced, the 
degree of inhibition by c7E3 Fab might have appeared more 
intense. 4) We did not perform counts of platelet surface 
GPIIb/IIIa receptors after stimulation with TRAP to deter- 
mine whether additional receptors were indeed expressed. 
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